PB2133: ASSESSING SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EPCORITAMAB IN NOVEL COMBINATIONS WITH ANTI-NEOPLASTIC AGENTS IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN A PHASE 1B/2, OPEN-LABEL STUDY

• L. H. Sehn,
• I. Avivi,
• J. Brody,
• D. H. Yoon,
• B. M. Elliott,
• S. R. Siddani,
• Y. Bai,
• A. Parikh,
• M. M. Seliem,
• M. H. Dinh,
• A. P. Skarbnik

Affiliations

L. H. Sehn

1 BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, Canada

I. Avivi

2 Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel

J. Brody

3 Icahn School of Medicine at Mount Sinai, New York, United States of America

D. H. Yoon

4 University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

B. M. Elliott

5 Genmab, Princeton

S. R. Siddani

6 AbbVie Inc., North Chicago

Y. Bai

6 AbbVie Inc., North Chicago

A. Parikh

6 AbbVie Inc., North Chicago

M. M. Seliem

6 AbbVie Inc., North Chicago

M. H. Dinh

6 AbbVie Inc., North Chicago

A. P. Skarbnik

7 Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, United States of America